Table 3. Top 8 articles investigating therapies in patients that present with metastatic pancreatic cancer (MPC), ranked according to overall survival (OS).
| OS | Title | Reference | Patients | Phase | Randomization |
|---|---|---|---|---|---|
| 717 days (strong DTH reactions) | Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer | Koido et al. Clin Cancer Res. 2014 | 10 | I | No |
| 18 months, 8.1 months after first-line therapy | Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort | Portal et al. Br J Cancer 2015 | 57 | II | No |
| 13.5 months | Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer | Ueno et al. Cancer Chemother Pharmacol 2016 | 34 | I/II | No |
| 13.5 months fluoro after GNP, 9.5 months fluoro after Gem | Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer | Chiorean et al. Br J Cancer 2016 | 347 | retrospective | |
| 11.9 months GEMOXEL, 7.1 months Gem | Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study | Petrioli et al. Cancer Chemother Pharmacol 2015 | 67 | II | Yes |
| 11 months FIRGEM, 8.2 months Gem | Fixed-dose rate gemcitabine alone or alternating with FOLFIRI3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM) | Trouilloud et al. Eur J Cancer 2014 | 98 | II | Yes |
Gem indicates gemcitabine, fluoro indicates fluoropyrimidine-based therapy, GNP indicates gemcitabine+nab-paclitaxel, DTH indicates delayed-type hypersensitivity.